Definition of Hypercoagulability, estrogen-associated

Hypercoagulability, estrogen-associated: Hypercoagulability (a supranormal tendency for blood to clot) occurs as an occasional but serious side effect of estrogen therapy.

The blood clots in this situation are dose-related, that is, they occur more frequently with higher doses of estrogen.

Estrogen therapy preparations (all of which carry this risk) include:

The brand names of the estrogen therapy preparations carrying this risk include:

  • CLIMARA (estradiol)
  • ESTRACE (estradiol)
  • ESTRADERM (estradiol)
  • ESTRATAB (esterified estrogens)
  • ESTRATEST (esterified estrogens and methyltestosterone)
  • MENEST (esterified estrogens)
  • OGEN (estropipate)
  • PREMARIN (estrogens conjugated)
  • PREMPHASE (estrogens conjugated and medroxyprogesterone)
  • PREMPRO (estrogens conjugated and medroxyprogesterone)

Cigarette smokers on estrogen therapy are at a higher risk than non-smokers for blood clots. Therefore, patients requiring estrogen therapy are strongly encouraged to quit smoking.


Last Editorial Review: 6/14/2012

Search MedTerms:


Back to MedTerms online medical dictionary A-Z List
Pill Identifier Tool

Need help identifying pills and medications?
Use the pill finder tool on RxList.